<unk> , sold under the brandname Defitelio, is a mixture of single-stranded oligonucleotides that is purified from the intestinal mucosa of pigs. It is used to treat veno-occlusive disease of the liver of people having had a bone marrow transplant, with different limitations in the US and the European Union. It works by protecting the cells lining blood vessels in the liver and preventing blood clotting; the way it does this is not well understood. The most common side effects include abnormally low blood pressure (hypotension), diarrhea, vomiting, nausea and nosebleeds (epistaxis). Serious potential side effects that were identified include bleeding (hemorrhage) and allergic reactions.<unk>  should not be used in people who are having bleeding complications or who are taking blood thinners or other medicines that reduce the body's ability to form clots. Use of the drug is generally limited by a strong risk of life-threatening bleeding in the brain, eyes, lungs, gastrointestinal tract, urinary tract, and nose. Some people have hypersensitivity reactions.<unk>  was approved for medical use in the European Union in October 2013, in the United States in March 2016, and in Australia in July 2020.<unk>  is the first FDA-approved therapy for treatment of severe hepatic VOD, a rare and life-threatening liver condition.
Defibrotide
Eptifibatide
Desmoteplase
Prokarin
Ticlopidine
Palladin
Tenecteplase
Ticagrelor